NCT06811831View on ClinicalTrials.gov

Evaluation of the Efficacy of MACitentan in the Treatment of CoronaryMICrovascular Angina (MACMIC)

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

November 1, 2024

Primary Completion Date

October 1, 2026

Study Completion Date

October 1, 2026

Conditions
Coronary Microvascular AnginaMacitentan
Interventions
DRUG

Macitentan 10 mg tablet, once daily.

After the patient signed an informed consent form, Macitentan was given as an oral medication (10 mg once daily) for a period of 4 weeks

Trial Locations (1)

100000

RECRUITING

China-Japan Friendship Hospital, Beijing

All Listed Sponsors
lead

China-Japan Friendship Hospital

OTHER